/R E P R I S E -- Avis aux médias - Montréal est au centre de l'actualité de la recherche et du traitement de la sclérose en plaques dans le cadre d'événements du 16 au 20 septembre 2008/



    MONTREAL, le 16 sept. /CNW Telbec/ - A la suite de l'événement VIVRE AVEC
LA SP s'adressant aux personnes atteintes de sclérose en plaques (SP) qui a
lieu mardi 16 septembre de 9h00 à 17h00 au CENTRE SHERATON, le grand congrès
mondial sur la recherche et le traitement de la sclérose en plaques sera le
décor de grandes premières du 17 au 20 septembre au PALAIS DES CONGRES DE
MONTREAL.
    Avec ses quelque 5200 participants dont des cliniciens et des chercheurs
scientifiques provenant de 55 pays, ce congrès mondial est la plus importante
conférence scientifique que le domaine ait jamais connu. C'est également la
première fois que les chercheurs d'Amérique du Nord, d'Amérique du Sud et
d'Europe se retrouvent pour l'occasion. Le premier Atlas mondial sur la SP y
sera présenté.
    En plus des nouvelles de dernière heure, il y aura 45 présentations
plateformes et 900 présentations par affichage couvrant les sujets les plus
importants reliés à la sclérose en plaques, en plus de 10 ateliers de
formation. Ces présentations seront faites par les plus grands spécialistes
mondiaux de la recherche et du traitement dans le domaine la sclérose en
plaques. Le recueil complet des résumés de présentations est disponible sur le
site Web du congrès au www.msmontreal.org, à la rubrique Program.

    
           EXTRAITS DU PROGRAMME SCIENTIFIQUE PRESENTE EN ANGLAIS

                         Mercredi 17 septembre 2008

    - Young Researchers Sessions - Including new work on identifying MS
    predictors and the implication of low levels of Vitamin D in children who
    develop MS, 14h45

    - Atlas of Multiple Sclerosis Launch - This is the most comprehensive
    study ever undertaken of the occurrence of multiple sclerosis around the
    world. The study focuses on the the global prevalence of MS and the
    resources available to diagnose, inform, treat, rehabilitate and support
    people with MS worldwide. More than 100 countries, representing almost
    88% of the world's population, participated in the study, undertaken by
    the World Health Organization and the Multiple Sclerosis International
    Federation, 19h00, Salle 516.

                           Jeudi 18 septembre 2008

    - Neurodegneration and inflammation - including presentations on
    reductions in brain volume across disease types, and nervous system
    repair/protection, 10h30-12h00

    - Brain plasticity and repair - including reports on mesenchymal stem
    cell injections (from patient's own bone marrow), 14h00-15h30

    - Pediatric MS - including studies on how age modifies MS profile,
    symptoms, and disease course, 15h30- 17h45

    - Costs and Availability of MS Treatments - including generics and
    biosimilar therapies, 17h00 - 17h45

    - Genomics and Proteomics in Understanding MS - including whether
    different disease courses display different genetic architecture and
    specific proteins influence MS relapses and remissions, 17h00 -17h45

    - Emerging Therapies posters - including studies on low-dose Naltrexone,
    a drug normally used to combat addiction, and its potential in
    preventing, delaying or reducing the severity of MS, 15h30 - 17h00

                         Vendredi 19 septembre 2008

    - Advances in imaging techniques - including metrics that might predict
    clinical disability, 10h30 - 12h00

    - Emerging Therapies - including an overview of oral and IV treatments in
    MS (14h00), studies on alemtuzumab's effect on reducing relapse rates vs.
    standard interferon (14h40), the results of a one year trial of a T-cell
    vaccination, Tovaxin, (14h55), and the first results from an early human
    trial of injections of mesenchymal stem cells (15h10)

    - Bone Marrow Transplantation - pros and cons, 17h00 - 17h45

    - Novel Cytokine, Chemokine and Adhesion Molecules - including adhesion
    molecules of the blood brain barrier and immunologic and clinical
    behavior in parasitic infection, 17h00 - 17h45

    - Better Understanding MS Disease Activity posters - including research
    examining why MS is usually more aggressive in the African-American
    population (15h30), and a study showing evidence that a gene linked to
    pain perception in healthy adults may also underlie differences in pain
    perception experienced by people with MS (15h30).

    - Possible MS Risk Factors posters - including a presentation focusing on
    latitudinal variation of sun exposure in the incidence of MS which
    explores the question of whether exposure to sunlight can protect people
    from developing MS (15h30)

    - Pediatric MS posters - including a study indicating that as many as 70%
    of children diagnosed with MS had psychiatric disorders in addition to
    MS, and a report that African-American children with MS in general
    experience more severe disease than children with MS from other racial or
    ethnic groups (15h30).

    - Emerging Therapies posters - includes a report on rituximab and its
    ability to treat breakthrough disease in people still taking a standard
    MS therapy (15h30)

                           Samedi 20 septembre 2008

    Late Breaking News on Emerging Therapies - including

    - rituximab a report that focuses on possible clues to the drug's
    beneficial activity in an unsuccessful trial in the more rare primary-
    progressive form of the disease, 8h30

    - a proof-of-concept study of the first antisense approach in MS, ATL1102
    that shows significant reduction in the accumulation of new brain
    lesions, 9h15

    - Low-dose Naltrexone poster that suggests it improved mental, but not
    physical, quality of life in people with MS, 10h00

    - Fampridine poster will present the results of a Phase 3 trial showing
    that the therapy could temporarily improve walking speed and leg
    strength. This is the first time the results of the 9-week trial, which
    will serve as the basis of an application for approval, will be presented
    to a public medical audience, 10h00

    LIEU: Palais des congrès de Montréal, 1001, Place Jean-Paul-Riopelle ou
          201, avenue Viger Ouest
          17-20 septembre. Mercredi, jeudi, vendredi de 8h30 à 17h30 et
          Samedi de 8h30 à 10h30.
    




Renseignements :

Renseignements: Bouba Slim, Cell.: (514) 777-1926, Salle de presse 521B,
bouba@boubaslim.com, www.msmontreal.org; Catherine Laramée, Cell.: (514)
772-3016, Salle de presse 521B, claramee@opus3.com, www.msmontreal.org

Profil de l'entreprise

WORLD CONGRESS ON TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.